JNJ vs. ABT

Last updated Apr 2, 2026

Compare and contrast key facts about Johnson & Johnson (JNJ) and Abbott Laboratories (ABT).

Performance

JNJ vs. ABT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Johnson & Johnson (JNJ) and Abbott Laboratories (ABT). The values are adjusted to include any dividend payments, if applicable.

JNJ vs. ABT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
JNJ Johnson & Johnson	18.59%	47.48%	-4.81%	-8.58%	5.97%	11.44%	10.82%	16.22%	-5.13%	24.43%
ABT Abbott Laboratories	-17.87%	12.87%	4.81%	2.26%	-20.68%	30.53%	28.04%	22.08%	29.06%	52.03%

Fundamentals

Market Cap JNJ : $595.41B ABT : $178.86B
EPS JNJ : $11.04 ABT : $3.73
PE Ratio JNJ : 22.12 ABT : 27.45
PEG Ratio JNJ : 0.74 ABT : 1.71
PS Ratio JNJ : 6.29 ABT : 4.04
PB Ratio JNJ : 7.30 ABT : 3.43
Total Revenue (TTM) JNJ : $94.19B ABT : $44.33B
Gross Profit (TTM) JNJ : $68.56B ABT : $24.61B
EBITDA (TTM) JNJ : $39.85B ABT : $11.33B

Returns By Period

In the year-to-date period, JNJ achieves a 18.59% return, which is significantly higher than ABT's -17.87% return. Both investments have delivered pretty close results over the past 10 years, with JNJ having a 11.40% annualized return and ABT not far behind at 11.33%.

JNJ

• 1D: -0.13%
• 1M: -1.79%
• YTD: 18.59%
• 6M: 32.75%
• 1Y: 63.73%
• 3Y*: 19.86%
• 5Y*: 11.54%
• 10Y*: 11.40%

ABT

• 1D: -0.28%
• 1M: -10.29%
• YTD: -17.87%
• 6M: -22.56%
• 1Y: -20.80%
• 3Y*: 2.36%
• 5Y*: -1.16%
• 10Y*: 11.33%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

JNJ vs. ABT — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JNJ

JNJ Risk / Return Rank: 97
JNJ Sharpe Ratio Rank: 98
JNJ Sortino Ratio Rank: 98
JNJ Omega Ratio Rank: 98
JNJ Calmar Ratio Rank: 95
JNJ Martin Ratio Rank: 97

ABT

ABT Risk / Return Rank: 7
ABT Sharpe Ratio Rank: 6
ABT Sortino Ratio Rank: 9
ABT Omega Ratio Rank: 8
ABT Calmar Ratio Rank: 10
ABT Martin Ratio Rank: 1

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JNJ vs. ABT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Johnson & Johnson (JNJ) and Abbott Laboratories (ABT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	JNJ	ABT	Difference
Sharpe ratio Return per unit of total volatility	3.67	-0.90	+4.57
Sortino ratio Return per unit of downside risk	4.95	-1.10	+6.05
Omega ratio Gain probability vs. loss probability	1.67	0.84	+0.82
Calmar ratio Return relative to maximum drawdown	6.09	-0.85	+6.94
Martin ratio Return relative to average drawdown	20.41	-2.13	+22.54
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

JNJ vs. ABT - Sharpe Ratio Comparison

The current JNJ Sharpe Ratio is 3.67, which is higher than the ABT Sharpe Ratio of -0.90. The chart below compares the historical Sharpe Ratios of JNJ and ABT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	JNJ	ABT	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	3.67	-0.90	+4.57
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.70	-0.05	+0.75
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.62	0.48	+0.14
Sharpe Ratio (All Time) Calculated using the full available price history	0.54	0.41	+0.13

Correlation

The correlation between JNJ and ABT is 0.49, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.

Dividends

JNJ vs. ABT - Dividend Comparison

JNJ's dividend yield for the trailing twelve months is around 2.13%, less than ABT's 2.34% yield.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
JNJ Johnson & Johnson	2.13%	2.48%	3.40%	3.00%	2.52%	2.45%	2.53%	2.57%	2.74%	2.38%	2.73%	2.87%
ABT Abbott Laboratories	2.34%	1.88%	1.95%	1.85%	1.71%	1.28%	1.32%	1.47%	1.55%	1.86%	2.71%	2.14%

Drawdowns

JNJ vs. ABT - Drawdown Comparison

The maximum JNJ drawdown since its inception was -50.67%, smaller than the maximum ABT drawdown of -55.57%. Use the drawdown chart below to compare losses from any high point for JNJ and ABT.

Drawdown Indicators

	JNJ	ABT	Difference
Max Drawdown Largest peak-to-trough decline	-50.67%	-55.57%	+4.90%
Max Drawdown (1Y) Largest decline over 1 year	-8.42%	-25.18%	+16.76%
Max Drawdown (5Y) Largest decline over 5 years	-18.41%	-33.88%	+15.47%
Max Drawdown (10Y) Largest decline over 10 years	-27.37%	-33.88%	+6.51%
Current Drawdown Current decline from peak	-1.79%	-25.62%	+23.83%
Average Drawdown Average peak-to-trough decline	-11.89%	-14.29%	+2.40%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.51%	10.05%	-7.54%

Volatility

JNJ vs. ABT - Volatility Comparison

The current volatility for Johnson & Johnson (JNJ) is 4.43%, while Abbott Laboratories (ABT) has a volatility of 5.96%. This indicates that JNJ experiences smaller price fluctuations and is considered to be less risky than ABT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	JNJ	ABT	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.43%	5.96%	-1.53%
Volatility (6M) Calculated over the trailing 6-month period	10.94%	16.81%	-5.87%
Volatility (1Y) Calculated over the trailing 1-year period	19.11%	23.10%	-3.99%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.67%	21.97%	-5.30%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	18.33%	23.57%	-5.24%

Financials

JNJ vs. ABT - Profitability Comparison

The chart below illustrates the profitability comparison between Johnson & Johnson and Abbott Laboratories over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a gross profit of 21.22B and revenue of 24.56B. Therefore, the gross margin over that period was 86.4%.

ABT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported a gross profit of 6.54B and revenue of 11.46B. Therefore, the gross margin over that period was 57.1%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported an operating income of 5.39B and revenue of 24.56B, resulting in an operating margin of 22.0%.

ABT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported an operating income of 2.25B and revenue of 11.46B, resulting in an operating margin of 19.6%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Johnson & Johnson reported a net income of 5.12B and revenue of 24.56B, resulting in a net margin of 20.8%.

ABT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Abbott Laboratories reported a net income of 1.78B and revenue of 11.46B, resulting in a net margin of 15.5%.